Insulet Corporation has announced its participation in the upcoming American Diabetes Association $(ADA.AU)$ 85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod® 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.